

	\$ millions, except EPS	FY19 Guidance	Pro Forma Growth vs. FY18
<b>Sales</b>	<b>Total</b>	<b>\$2,633 - \$2,667</b>	<b>~6 – 7.5%</b>
	<b>CooperVision</b>	<b>\$1,964 - \$1,985</b>	<b>~7 – 8%</b>
	<b>CooperSurgical</b>	<b>\$669 - \$682</b>	<b>~4 – 6%</b>
<b>EPS</b>	<b>Non-GAAP</b>	<b>\$12.15 - \$12.35</b>	

Represents management guidance as revised 5/30/19

Note: Non-GAAP and Pro Forma – Refer to earnings releases for definitions and reconciliation of results